Carrasco Esther, Álvarez Pablo Juan, Melguizo Consolación, Prados José, Álvarez-Manzaneda Enrique, Chahboun Rachid, Messouri Ibtissam, Vázquez-Vázquez María Isabel, Aránega Antonia, Rodríguez-Serrano Fernando
Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, 18071 Granada, Spain; PhD Program in Biomedicine, University of Granada, 18071 Granada, Spain.
Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, 18071 Granada, Spain.
Eur J Med Chem. 2014 May 22;79:1-12. doi: 10.1016/j.ejmech.2014.03.071. Epub 2014 Mar 25.
This article describes the antitumor properties of a new family of merosesquiterpenes, which were synthesized by Diels-Alder cycloaddition of the labdane diene trans-communic acid, highly abundant in Cupressus sempervirens, or its methyl ester, with the appropriate dienophile. These compounds demonstrated potent cytotoxic activity in vitro against human breast, colon, and lung tumor cells. We highlight the elevated activity (IC50: 0.35 ± 0.10 μM) and specificity (TI: 9) of compound 13 against the MCF-7 line, which corresponds to the most prevalent breast cancer cell subtype, luminal A. It was found that compound 13 exerts its anti-tumor action by inducing oxidative stress, arresting the cell cycle in stages G0-G1, and activating apoptosis, which are all associated with low cyclin D1 regulation, pRb hypophosphorylation, increased expression of p27 and p53, and poly (ADP-ribose) polymerase (PARP) fractioning. Epithelial-mesenchymal transition, a phenomenon associated with metastasis promotion and a worsened prognosis also appeared to be inhibited by compound 13. In addition, it markedly reduced tumor development in immunocompetent C57BL/6 mice with allografts of E0771 mouse breast tumor cells (luminal A subtype). According to these findings, this new family of compounds, especially compound 13, may be highly useful in the treatment of human breast cancer.
本文描述了一个新的半萜烯类化合物家族的抗肿瘤特性,这些化合物是通过在富含地中海柏木的半日花烷二烯反式-communic酸或其甲酯与合适的亲双烯体之间进行狄尔斯-阿尔德环加成反应合成的。这些化合物在体外对人乳腺癌、结肠癌和肺癌细胞显示出强大的细胞毒活性。我们强调了化合物13对MCF-7细胞系(对应于最常见的乳腺癌细胞亚型腔面A型)具有较高的活性(IC50:0.35±0.10μM)和特异性(TI:9)。研究发现,化合物13通过诱导氧化应激、使细胞周期停滞在G0-G1期以及激活凋亡来发挥其抗肿瘤作用,这些都与细胞周期蛋白D1低调节、pRb低磷酸化、p27和p53表达增加以及聚(ADP-核糖)聚合酶(PARP)裂解有关。上皮-间质转化是一种与转移促进和预后恶化相关的现象,似乎也受到化合物13的抑制。此外,它显著减少了具有E0771小鼠乳腺肿瘤细胞(腔面A型亚型)同种异体移植的免疫活性C57BL/6小鼠中的肿瘤发展。根据这些发现,这个新的化合物家族,尤其是化合物13,可能在人类乳腺癌治疗中非常有用。